EU To Review AHP Offer FoR Cyanamid

4 September 1994

The proposed takeover of American Cyanamid by American Home Products is to be examined by the European Commission to see if it is in conformity with European Union rules on competition. The commission was notified of the deal on August 16, and on August 24 it said that on the basis of its preliminary examination of the proposal, it could fall within the scope of the EU Merger Regulation.

The fact that the deal is under investigation by the EU competition authorities does not of itself mean it is likely to be called off or prohibited. Sources in Brussels say that the EU is likely to clear the deal within weeks.

Towards the end of August the US Federal Trade Commission requested additional information in connection with the previously-announced tender offer for shares in American Cyanamid common stock (Marketletters passim).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight